26
Feb
2023
The Success of Your Tech Deployment Depends On A Role You’ve Probably Never Heard Of
The success or failure of many technology platforms — including in particular health tech platforms — rests with a largely obscure role of outsized importance: the “solutions engineer.” The role itself goes by many names. Back when I was at DNAnexus in the mid-2010s, this role was called “Solutions Scientist.” Others call it “Forward-Deployed Engineer” or “Embedded Analyst.” Whatever the... Read More
14
Feb
2023
Engineered B-Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run
Today’s guest on The Long Run is Joanne Smith-Farrell. Joanne is the CEO of Cambridge, Mass.-based Be Biopharma. Many listeners of this show are familiar with the explosion of activity in cell therapy. Engineered T cell therapies have delivered extraordinary results for people with certain types of cancer. The success in these personalized T cell therapies, which get modified outside... Read More
10
Feb
2023
Why Is It So Hard to Get Patients the Medicines They Need?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Feb
2023
First, We Need to Generate the Right Data. Then AI Will Shine
ChatGPT is a hot topic across many industries. Some say the technology underpinning it – called generative AI – has created an “A.I. arms race.” However, relatively little attention is given to what is needed to fully leverage the promise of generative AI in healthcare, and specifically how it may help accelerate drug discovery and development. That’s a mistake. Recently,... Read More
4
Feb
2023
Grand Défi Ou Goulot D’étranglement Ultime: A French Pharma Tackles Data Science
Most biopharma companies have started down the path of digital transformation – a fundamental overhaul of everything they do for the digital age. It’s not clear yet that anyone has arrived at the desired destination. Even so, there have been some early wins, generally related to operations, as the CEOs of both Novartis and Lilly have described. Arguably, the most... Read More
2
Feb
2023
GSK, Lilly Win FDA Approvals, Magenta For Sale, and a Colossal Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2023
When Life-Saving Medicines Are Ammunition in a Trade War
In early January, I held a telemedicine visit with a patient who reported a positive at-home COVID test and mild shortness of breath. During the visit, I looked through her health conditions and medications and decided that it was appropriate to prescribe Paxlovid. Later that day, she received the prescription from her local pharmacy, free of charge. Afterwards, I called... Read More
1
Feb
2023
A Biotech Journalism Outlet Built to Last: Rick Berke on The Long Run
Today’s guest on The Long Run is Rick Berke. Rick is the co-founder and executive editor of STAT. Just about everyone who listens to The Long Run probably already reads STAT. If you don’t, you should. It’s become a go-to publication for breaking news, features, and in-depth investigative reporting across the world of biotech and healthcare. John Henry, the billionaire... Read More
31
Jan
2023
Rebounding From a Setback With a Transformative Partnership
One of the well-known rituals at many companies is the holiday party. It’s a way to unwind after a long and demanding year and get to know our colleagues better. The January gathering was extra special at Spero Therapeutics. This was our first in-person holiday celebration in three years. We gathered at a hotel in Cambridge, not far from the... Read More
30
Jan
2023
Generative AI: No Humbug
In 1845, dentist Horace Wells stood before Harvard medical students and faculty, eager to demonstrate the utility of nitrous oxide – laughing gas – as a general anesthetic. Wells tried it out on a patient who needed a tooth extraction. The dose, it turned out, wasn’t enough. The patient screamed in agony. As described by Paul Offit in You Bet... Read More
26
Jan
2023
VIR’s Scangos Retires, Pliant’s IPF Win, & Some Painful Decisions
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jan
2023
Dimension Debuts with $350M to Back Startups at Bio & Tech Nexus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Jan
2023
Biotech Needs to Get Back to Work in Person. Now.
Companies at the frontiers of science and medicine, developing new therapies for patients, are working on one of the most challenging endeavors known to humanity. Most would agree it’s more difficult than putting a man on the moon. The pandemic created a dramatic disruption to our globally networked economy. It will have far-ranging and long-lasting repercussions. It started with quarantine.... Read More
19
Jan
2023
From Computational Discovery to a New Psoriasis Drug: Jeb Keiper on The Long Run
Today’s guest on The Long Run is Jeb Keiper. Jeb is the CEO of Boston-based Nimbus Therapeutics. Nimbus made news in December 2022 when it sold its experimental Tyk2 inhibitor to Takeda Pharmaceuticals for $4 billion upfront and $2 billion in potential milestones. The drug’s value skyrocketed when it hit the primary endpoint of a Phase 2b clinical trial for... Read More
19
Jan
2023
Concert Gets Acquired, Structure Tees Up IPO, & a Proposed Noncompete Ban
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
12
Jan
2023
JPM Vibes, Verily Cuts Back, & Eisai’s Transparent Price
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2023
J&J Walks Away from Fate, Century Cuts Back, & Moderna’s Strategic Buy
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2023
Oui Therapeutics: Shifting the Clinical, Societal and Business Impact of Suicide
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2023
Belharra Gets $130M from Versant, Genentech For Chemoproteomic Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2023
From Musician to Tech to Biotech Investor: D.A. Wallach on The Long Run
Today’s guest on The Long Run is D.A. Wallach. D.A. is the founder and general partner of Time BioVentures. Time BioVentures is a relative newcomer to the biotech world, investing out of a $100 million inaugural fund. The strategy is to invest in companies seeking to make a big impact in therapeutics, diagnostics, research tools, and healthcare delivery models. D.A.... Read More